Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Catalent's $1.2B Paragon buy positions the CDMO for the AAV gold rush, with ~$200M expected 2019 revenue and signed contracts already covering the majority of…
FDA approved manufacture of Sarepta's Elevidys drug substance at Catalent's Harmans, Maryland facility — capacity added via the 2019 $1.2B Paragon Bioservices…
Catalent announced ~350 layoffs at its Harmans/BWI viral-vector site (former Paragon Bioservices) citing an unexpected demand shift from a large customer.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Catalent acquired Paragon Bioservices for $1.2 billion in cash, adding viral vector (AAV/lentivirus) capabilities to support gene therapy and biologics CDMO services. Announced April 15, 2019; closed May 17, 2019. The thesis was validated post-close: the former Paragon site in Harmans, Maryland (near BWI) became a commercial viral-vector manufacturing hub for Novartis's Zolgensma and, after FDA approval in 2023, the drug-substance site for Sarepta's Elevidys. Catalent — including the former-Paragon gene therapy platform — was subsequently acquired by Novo Holdings in an all-cash deal (~$16.5B enterprise value, $63.50/share) completed December 18, 2024, with the stock delisted from the NYSE. In August 2025 Catalent announced ~350 layoffs at the Harmans viral-vector site citing a demand shift from a large customer.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Catalent, Inc. / Paragon Bioservices, Inc. (this deal) | 2019 | $1.2B | — |
| Catalent, Inc. / Bettera Holdings, LLC | 2021 | $1.0B | — |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2019 deals · Gene Therapy deals